von Ardenne M, von Ardeene A, Krüger W
Acta Biol Med Ger. 1977;36(9):1199-212.
The authors describe methods and results on the aglycon liberation from several glucuronides using beta-flucuronidase in vitro. The glucuronides examined are prototypes of new potent anticancer drugs (so-called CMT selectines). Basing on the knowledge of the values and parameters involved theoretical considerations result in evaluation of the anticipated selective action of CMT selectines in artificially hyperacidified cancer tissues compared to normal tissues. The equations derived from certain mathematical simplifications are presented. The calculated high selectivity S approximately 20 can only be realized in vivo if the "masking index" s as to toxic action and renal clearance of a chosen CMT selectine is greater than 20. In fact, the hitherto known CMT selectines exhibit sufficiently high masking indices that the realization of a true transportation form/active form principle using different cancerotoxic agents as aglycones can be assumed.
作者描述了在体外使用β-葡萄糖醛酸酶从几种葡萄糖醛酸苷中释放苷元的方法和结果。所检测的葡萄糖醛酸苷是新型强效抗癌药物(所谓的CMT 选择素)的原型。基于所涉及的数值和参数的知识,理论考量得出了与正常组织相比,CMT 选择素在人工酸化的癌组织中预期的选择性作用的评估结果。文中给出了通过某些数学简化推导得出的方程式。计算得出的高选择性S约为20,只有当所选CMT选择素的毒性作用和肾清除率的“掩蔽指数”s大于20时,才能在体内实现。事实上,迄今为止已知的CMT选择素表现出足够高的掩蔽指数,因此可以假定使用不同的癌毒性剂作为苷元来实现真正的转运形式/活性形式原理。